Adipose-derived SVF for Treatment of Alopecia

Inclusion criteria

• Males and females 18 - 60 years of age and older that have been diagnosed with androgenetic alopecia.
• Subjects will be in good health (ASA Class I-II) with a BMI < 35. Must have at least a 2cm x 2cm spot on the scalp which shows evidence of alopecia without scarring or traumatic injury
• Able and willing to make the required study visits.
• Able and willing to give consent and follow study instructions.
• Must speak, read and understand English

Exclusion criteria

• History of bleeding disorders, anticoagulation therapy that cannot be stopped 14 days prior to injection
• Allergic to lidocaine, epinephrine, valium or sodium phosphate
• Individuals with a propensity for keloids
• Individuals with diminished decision-making capacity will not be included in this research study
• Current use of anti-inflammatory or anticoagulation medications that affect bleeding or are for bleeding disorders. These include: Plavix, Warfarin (Coumadin, Jantoven, Marfarin). In addition, if any of the following medicines are used two (2) weeks prior to surgery the patient will be ineligible.
• Use of concomitant treatments, including topical medications, oral medications, meso-therapy, non-ablative fractional laser treatment, low-level laser therapy, interfollicular PRP injection and hair transplantation within the preceding 6 months.
• All smokers and other tobacco users.